Addus HomeCare Corporation (ADUS) Next Earnings Date & Expected ±4.7% Move

ADUS carries an RQD Score of 73, a letter grade of B, and the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 12 / 20. Per the RQD rating, this pillar cites ROIC of 9.1% and FCF yield of 4.47%. This is the lowest-scoring pillar, indicating that cash generation relative to capital and valuation is only moderately supportive of the thesis. An investor should note that the FCF yield of 4.47% is the main valuation anchor for cash-based reasoning.
• Whale 13F Flow: 16 / 20. The RQD rating describes institutional accumulation and options positioning as a relative strength. This suggests larger holders have been net constructive, though the holder-level data supporting this pillar is not itemized in the source data.
• Insider Conviction: 15 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow contribute a moderately positive signal. The underlying transaction detail is not itemized in the source data.
• Macro Regime Fit: 15 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is cited. A beta of 1.0 means the stock is described as moving in line with the broad market, so macro regime shifts would be expected to affect it roughly proportionally.
• Forensic Balance Sheet: 15 / 20. Per the RQD rating, Altman Z is 5.83, Piotroski F is 9/9, and Debt/Equity is 0.11. These are the strongest forensic readings in the source data and point to a low-leverage, financially sound profile.

For a prospective investor evaluating the stock today, the pillar mix implies that the case rests more on balance sheet strength and institutional/insider positioning than on cash-generation efficiency. Valuation is a tradeoff: per the market data, P/E (TTM) is 24.2 versus a forward P/E of 20.3, which implies expected earnings growth is embedded in the forward estimate, while EV/EBITDA of 16.8 is not compared to a peer benchmark in the source data. The upside drivers cited are the forensic strength and positioning flow; the main constraint is the 9.1% ROIC and 4.47% FCF yield. Ripple effects from the sector are not quantified in the source data. This analysis is educational and not personalized financial advice.

Addus HomeCare Corporation is a NASDAQ-listed issuer classified in the Health Care sector and Medical/Nursing Services industry. Its market capitalization is $2.3B. Specific products, customer segments, and revenue mechanics beyond sector and industry classification are —

Revenue rose from $1.06B in FY 2023 to $1.42B in FY 2025, and net income rose from $62.5M to $95.9M over the same span. Per the market data, gross margin is 32.5%, operating margin 9.7%, and net margin 6.7%, with ROIC of 9.1%. The Altman Z-Score is 5.83 and the Piotroski F-Score is 9/9. Per the RQD rating, Debt/Equity is 0.11, and the financials show debt declining from $218.4M in FY 2024 to $121.0M in FY 2025. FCF declined modestly across the three periods, from $112.2M to $103.8M.

• 🐂 Primary Bull Case: Per the RQD rating, forensic balance sheet strength (Altman Z 5.83, Piotroski F 9/9, Debt/Equity 0.11) combined with institutional accumulation supports the Roarable Buy verdict. With Fundamental Cash Engine at 12/20 (ROIC 9.1%, FCF yield 4.47%) and Institutional Whale Flow at 17/20, sustained execution supports upside toward the top of the $87.95 – $126.62 52-week range.
• 🐻 Primary Bear Case: Per the RQD rating, the Fundamental Cash Engine scores only 12 / 20 with ROIC of 9.1% and FCF yield of 4.47%, and FCF declined from $112.2M to $103.8M. Investors must weigh 24.2x trailing P/E and 16.8x EV/EBITDA against 9.7% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies: — Sector correlations beyond the stated beta of 1.0: — 2nd-order bottlenecks: — An investor should treat the absence of mapped links as a gap in the analysis rather than as evidence of independence.

• Key Question #1: What are the reported EPS and cash balances for FY 2025 and FY 2023, which are currently marked as unavailable?
• Key Question #2: What drove the decline in FCF from $112.2M to $103.8M despite rising net income?
• Key Question #3: How sensitive is ADUS's 32.5% gross margin and 20.3x forward P/E multiple to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?